Please assess the completion status of the following clinical trial:

Trial Title: PBASE-system Acute Migraine Clinical Investigation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent prior to participation in the clinical investigation~* Male or female aged between 18 and 65 years~* Diagnosed as suffering from migraine with or without aura according to IHS classification (ICHD-II)~* Reported history of 2 to 6 migraine episodes per month during previous 3 months, confirmed during a prospective baseline period of one month~* Reported history of no less than 50% of migraine episodes involving moderate or severe pain intensity, confirmed during a prospective baseline period of one month~* Reported history of at least 48 hours of freedom from headache between migraine attacks, confirmed during a prospective baseline period of one month~* Reported history of the majority of untreated migraine attack durations lasting 8 hours or more~* Onset of migraine headache occured before age 50~* Reported history of migraine for more than one year~* Able and willing to maintain current preventive headache medication regimen(s) (no change in type, frequency or dose) from baseline screening visit to 2 weeks post-treatment~* Able to understand and complete the electronic diary~* Experiencing an acute migraine attack of moderate to severe pain intensity at the time of treatment~* Treatment is possible within 5 hours of migraine onset~Exclusion Criteria:~* Reported history of 15 or more headache days per month (i.e. headaches of any kind), confirmed during a prospective baseline period of one month~* Reported frequency of non-migraine headaches exceeding 6 days per month, confirmed during a prospective baseline period of one month~* Unable to distinguish between migraine headaches and other headache types at the onset of a migraine attack~* Treatment with Botox received within 6 months of the screening visit, or between the screening and treatment visit~* Previously treated with an implantable stimulator or any implantable devices in the head and/or neck~* Diagnosed as having a pronounced anterior septal deviation~* History of sinus surgery, transphenoidal surgery for pituitary or other lesions or CSF rhinorrhea~* Fitted with a pacemaker /defibrillator~* Previously treated with radiation to the face~* Ongoing bacterial infection in the nasal cavity~* History of nose bleeds (epistaxis)~* Ongoing malignancy in the nasal cavity~* Concomitant condition that could cause excessive bleeding~* Known allergy to polyvinylchloride,the material used for fabrication of the balloon part of Catheter A100, or medicinal liquid paraffin~* Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation~* Any change in migraine prophylaxis between the screening and treatment visit~* Women of childbearing potential who is pregnant or at risk of becoming pregnant prior to or during the treatment phase~* Participation in a clinical research study within 3 months of enrolment or planned participation at any time during this clinical investigation~* Considered to meet the definition of vulnerable in the Investigator's opinion~* Headache or migraine episode within the 48 hours prior to treatment~* PRN (as required) or acute migraine medication(s) taken within the 48 hours prior to treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PBASE-system 2.0 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues